Stay updated on COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Sign up to get notified when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.

Latest updates to the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added as the latest version in the study's history, replacing the earlier v3.4.1. The notice about government funding and operating status was removed from the page.SummaryDifference0.3%

- Check21 days agoChange DetectedThe page shows two minor administrative updates: a site-wide notice regarding government funding and a new revision tag (v3.4.1) that supersedes v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedThe history page adds a glossary display option and color-coded highlights for additions and deletions, and updates the revision label from v3.3.4 to v3.4.0.SummaryDifference0.3%

- Check42 days agoChange DetectedRevision history updated: added Revision v3.3.4 and removed Revision v3.3.3.SummaryDifference0.0%

- Check64 days agoChange DetectedA new Revision: v3.3.3 was added, and the HHS Vulnerability Disclosure link as well as the previous Revision: v3.3.2 entry were removed.SummaryDifference0.1%

- Check85 days agoChange DetectedThe page history shows a minor revision update (v3.3.2) replacing v3.3.1, a footer-level change with no impact on core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Enter your email address, and we'll notify you when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.